Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (Diluted Average) (2016 - 2025)

Plus Therapeutics has reported Shares Outstanding (Diluted Average) over the past 11 years, most recently at $77.8 million for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 910.35% to $77.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.8 million through Dec 2025, up 910.35% year-over-year, with the annual reading at $77.8 million for FY2025, 910.35% up from the prior year.
  • Shares Outstanding (Diluted Average) was $77.8 million for Q4 2025 at Plus Therapeutics, up from $57.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $77.8 million in Q4 2025 and troughed at $1.5 million in Q2 2022.
  • The 5-year median for Shares Outstanding (Diluted Average) is $7.7 million (2024), against an average of $14.6 million.
  • Year-over-year, Shares Outstanding (Diluted Average) plummeted 89.21% in 2023 and then soared 910.35% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $12.1 million in 2021, then tumbled by 85.52% to $1.8 million in 2022, then surged by 79.45% to $3.1 million in 2023, then soared by 145.18% to $7.7 million in 2024, then soared by 910.35% to $77.8 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Shares Outstanding (Diluted Average) are $77.8 million (Q4 2025), $57.8 million (Q3 2025), and $24.4 million (Q2 2025).